-
Results of two case-control studies indicate that women without risk factors for venous thromboembolism (VTE) who use oral contraceptives (OCs) containing drospirenone have an increased risk for nonfatal VTE compared with those who use levonorgestrel OCs.
-
A just-published study indicates that many providers are failing to counsel women on the availability of emergency contraception (EC).
-
Add another human papillomavirus (HPV) test to the clinical arsenal. The Food and Drug Administration (FDA) has approved the Roche cobas HPV Test.
-
One woman in five develops a urinary tract infection (UTI) during her lifetime, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
-
For four decades, safety-net providers such as community health centers have turned to the National Health Service Corps (NHSC) for help with maintaining a well-trained and credentialed workforce.
-
What will it take to drive down the number of chlamydia infections in young women? While routine chlamydia screening is recommended for all sexually active females age 24 years and younger, only about half (49.9%) were screened during 2008-09, according to data collected in more than 1,000 U.S. health plans.
-
In a Phase 3 trial comparing the recently introduced monoclonal antibody denosumab with zoledronic acid for the treatment of patients with prostate cancer metastatic to bone, the incidence of skeletal events including pathological fracture, radiation, skeletal surgery, or cord compression was delayed on average by more than 3 months for those treated with denosumab. Adverse events were comparable. Denosumab is administered subcutaneously and can be given to patients with renal insufficiency. Clinicians have become familiar with zoledronic acid in this setting, and it remains unclear whether its role as the standard approach will be supplanted.
-
Deep vein thrombosis (DVT) and pulmonary embolus (PE) occur more frequently in patients with cancer, and the risk appears to vary by tumor type.
-
-
Investigators prospectively assessed quality of life in newly diagnosed AML patients 60 years and older using the EORTC QLC-C30 and QOL-E surveys. Among the 113 patients enrolled, 42.4% underwent intensive induction chemotherapy and 57.6% received palliative treatment. Self-rated quality of life did not correlate with physician-rated performance status or induction chemotherapy. Lower self-report functional status predicted higher mortality, even after adjusting for age, treatment, and comorbidity. Patient-reported quality of life may be an independent prognostic factor for AML outcomes.
